The Inhalation Advantage
Faster and more affordable development of inhaled medicines
sponsored by Vectura
Vectura has more than 20 years’ experience in helping customers bring inhaled medicines to the market, and integrates formulation, device and development capabilities to offer a broad range of services to accelerate inhaled products through the phases of drug development. Having expertise in product formulation and device development across a number of platforms offers customers both flexibility and continuity, forging true collaborative partnerships to combine the right drug with the right device.
The trend within the industry to find new uses for old drugs has increased, and might take a drug already approved for one indication, and find utility in another; or create a new formulation to allow administration via a different route for the same indication. Alternatively, an existing drug may have its product profile improved or altered, while keeping the same administration route. Either way, as well as providing advantages for patients, it can offer new intellectual property coverage, driving additional revenue for innovators with lower risk and faster entry to market.
Inhaled delivery offers opportunities for improved dosing, simpler, less invasive administration, enhanced patient adherence, and product lifecycle management. By repurposing known drugs and leveraging pre-existing drug safety data, manufacturers benefit from shorter, less costly and less risky development programs, which has been particularly relevant for accelerating the progression of COVID-19 products.
In a recent webinar, Geraldine Venthoye, Chief Scientific Officer and Executive Vice President, Product Development at Vectura, discusses the value of inhaled drug delivery, and how repurposing or repositioning a drug can represent a safer, faster and more affordable way to develop new products than de novo drug discovery and development.
Dr. Venthoye also reviews the recent interest in inhaled COVID-19 products, choosing devices for repurposed products, device selection for repurposed biologics, and mitigating the environmental impact of devices. The webinar is available at https://bit.ly/3pdBQTD